Sanofi (SNY)

FR — Healthcare Sector
Peers: AZN  RHHBY  GSK  MRK  NVS  BMY  GILD  BAYRY  AMGN  ABBV  JNJ 

Automate Your Wheel Strategy on SNY

With Tiblio's Option Bot, you can configure your own wheel strategy including SNY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol SNY
  • Rev/Share 35.4761
  • Book/Share 60.3112
  • PB 0.7972
  • Debt/Equity 0.2841
  • CurrentRatio 1.3662
  • ROIC 0.0604

 

  • MktCap 116608872127.0
  • FreeCF/Share 1.2878
  • PFCF 73.3851
  • PE 9.3752
  • Debt/Assets 0.1596
  • DivYield 0.0462
  • ROE 0.0848

 

  • Rating B+
  • Score 3
  • Recommendation Neutral
  • P/E Score 2
  • DCF Score 4
  • P/B Score 3
  • D/E Score 2

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation SNY Exane BNP Paribas -- Outperform -- $65 April 15, 2025
Initiation SNY Goldman -- Neutral -- $65 March 21, 2025
Upgrade SNY Deutsche Bank Sell Hold -- -- Jan. 30, 2025

News

Press Release: Filing of the 2024 U.S. Form 20-F and French “Document d'Enregistrement Universel” containing the Annual Financial Report
SNY
Published: February 13, 2025 by: GlobeNewsWire
Sentiment: Neutral

Filing of the 2024 U.S. Form 20-F and French “Document d'Enregistrement Universel” containing the Annual Financial Report Paris, February 13, 2025. Sanofi announces today the filing of its Form 20-F with the U.S. Securities and Exchange Commission (SEC) and its “Document d'Enregistrement Universel” containing its Annual Financial Report with the French market regulator Autorité des marchés financiers (AMF).

Read More
image for news Press Release: Filing of the 2024 U.S. Form 20-F and French “Document d'Enregistrement Universel” containing the Annual Financial Report
Press Release: Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study
SNY
Published: February 13, 2025 by: GlobeNewsWire
Sentiment: Neutral

Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study Independent interim analysis of the E.mbrace phase 3 study finds that the vaccine candidate didn't demonstrate sufficient efficacy in preventing invasive E.

Read More
image for news Press Release: Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study

About Sanofi (SNY)

  • IPO Date 2002-07-01
  • Website https://www.sanofi.com
  • Industry Drug Manufacturers - General
  • CEO Mr. Paul Hudson
  • Employees 82878
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.